S&P Futures
3,301.50+38.00(+1.16%)Dow Futures
26,706.00+297.00(+1.12%)Nasdaq Futures
11,263.00+130.25(+1.17%)
ACADIA Pharmaceuticals Inc. (ACAD)
Chart Events
Performance Outlook
| Previous Close | 46.36 |
| Open | 45.90 |
| Bid | 0.00 x 1000 |
| Ask | 0.00 x 1300 |
| Day's Range | 45.32 - 47.75 |
| 52 Week Range | 30.02 - 58.72 |
| Volume | 1,910,323 |
| Avg. Volume | 1,200,558 |
| Market Cap | 7.374B |
| Beta (5Y Monthly) | 1.43 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.47 |
| Earnings Date | Nov 04, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 59.33 |
- Zacks
Earnings Preview: Acadia Pharmaceuticals (ACAD) Q3 Earnings Expected to Decline
Acadia (ACAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Insider Monkey
Were Hedge Funds Wrong About Embracing ACADIA Pharmaceuticals Inc. (ACAD)?
Many prominent investors, including Warren Buffett, David Tepper and Stan Druckenmiller, have been cautious regarding the current bull market and missed out as the stock market reached another high in recent weeks. On the other hand, technology hedge funds weren’t timid and registered double digit market beating gains. Financials, energy and industrial stocks aren’t doing […]
- Business Wire
Acadia Pharmaceuticals to Present New Scientific Data on Pimavanserin in Neurodegenerative Diseases at the 13th Clinical Trials on Alzheimer's Disease (CTAD) Conference
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that scientific presentations highlighting new analyses of pimavanserin clinical study data in dementia-related psychosis and neurodegenerative diseases will be shared at the 13th Clinical Trials on Alzheimer's Disease Conference (CTAD), being held virtually November 4-7, 2020.
